References
- Cyranoski D. Alarming COVID variants show vital role of genomic surveillance. Nature. 2021 Jan;589(7842):337–338. DOI:https://doi.org/10.1038/d41586-021-00065-4. PMID: 33452508.
- Shen L, Maglinte DT, Ostrow D, et al. Children’s Hospital Los Angeles COVID-19 Analysis Research Database (CARD) – A resource for rapid SARS-CoV-2 genome identification using interactive online phylogenetic tools. bioRxiv. 2020. DOI:https://doi.org/10.1101/2020.05.11.089763
- Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID’s innovative contribution to global health. Glob Chall. 2017 Jan 10;1(1):33–46. DOI:https://doi.org/10.1002/gch2.1018. PMID: 31565258; PMCID: PMC6607375.
- Shu Y, McCauley J. GISAID: global initiative on sharing all influenza data – from vision to reality. Euro Surveill. 2017 Mar 30;22(13):30494, DOI:https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494. PMID: 28382917; PMCID: PMC5388101.
- Shen L, Dien Bard J, Biegel JA, et al. Comprehensive genome analysis of 6000 USA SARS-CoV-2 isolates reveals haplotype signatures and localized transmission patterns by state and by country. Front Microbiol. 2020 Sep 3;11:573430. DOI:https://doi.org/10.3389/fmicb.2020.573430. PMID: 33013809; PMCID: PMC7509426.
- Pandey U, Yee R, Shen L, et al. High prevalence of SARS-CoV-2 genetic variation and D614G mutation in pediatric patients with COVID-19. Open Forum Infect Dis: ofaa551. DOI:https://doi.org/10.1093/ofid/ofaa551.
- Katoh K, Misawa K, Kuma K, et al. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res. 2002 Jul 15;30(14):3059–3066. DOI:https://doi.org/10.1093/nar/gkf436. PMID: 12136088; PMCID: PMC135756.
- Minh BQ, Schmidt HA, Chernomor O, et al. IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. Mol Biol Evol. 2020 May 1;37(5):1530–1534. DOI:https://doi.org/10.1093/molbev/msaa015. PMID: 32011700; PMCID: PMC7182206.
- Sagulenko P, Puller V, Neher RA. Treetime: maximum-likelihood phylodynamic analysis. Virus Evol. 2018 Jan 8;4(1):vex042. DOI:https://doi.org/10.1093/ve/vex042. PMID: 29340210; PMCID: PMC5758920.
- Ittisoponpisan S, Islam SA, Khanna T, et al. Can predicted protein 3D structures provide reliable insights into whether missense variants are disease associated? J Mol Biol. 2019 May 17;431(11):2197–2212. DOI:https://doi.org/10.1016/j.jmb.2019.04.009. Epub 2019 Apr 14. PMID: 30995449; PMCID: PMC6544567.
- Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020 Aug 20;182(4):812–827. DOI:https://doi.org/10.1016/j.cell.2020.06.043. Epub 2020 Jul 3. PMID: 32697968; PMCID: PMC7332439.
- Walensky RP, Walke HT, Fauci AS. SARS-CoV-2 variants of concern in the United States-challenges and opportunities. JAMA. 2021 Feb 17. DOI:https://doi.org/10.1001/jama.2021.2294. Epub ahead of print. PMID: 33595644
- Yoshimoto FK. The proteins of severe acute respiratory syndrome coronavirus-2 (SARS CoV-2 or n-COV19), the cause of COVID-19. Protein J. 2020 Jun;39(3):198–216. DOI:https://doi.org/10.1007/s10930-020-09901-4. PMID: 32447571; PMCID: PMC7245191.
- Lu S, Ye Q, Singh D, et al. The SARS-CoV-2 nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein. Nat Commun. 2021 Jan 21;12(1):502. DOI:https://doi.org/10.1038/s41467-020-20768-y. PMID: 33479198; PMCID: PMC7820290.
- Zheng Y, Zhuang MW, Han L, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling. Signal Transduct Target Ther. 2020 Dec 28;5(1):299. DOI:https://doi.org/10.1038/s41392-020-00438-7. PMID: 33372174; PMCID: PMC7768267.
- Liu J, Sun Y, Qi J, et al. The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes. J Infect Dis. 2010 Oct 15;202(8):1171–1180. DOI:https://doi.org/10.1086/656315. PMID: 20831383; PMCID: PMC7537489.
- Griffin DE. Are T cells helpful for COVID-19: the relationship between response and risk. J Clin Invest. 2020 Dec 1;130(12):6222–6224. DOI:https://doi.org/10.1172/JCI142081. PMID: 32976117; PMCID: PMC7685712.
- Sattler A, Angermair S, Stockmann H, et al. SARS-CoV-2-specific T cell responses and correlations with COVID-19 patient predisposition. J Clin Invest. 2020 Dec 1;130(12):6477–6489. DOI:https://doi.org/10.1172/JCI140965. PMID: 32833687; PMCID: PMC7685725.
- Ledford H. How ‘killer’ T cells could boost COVID immunity in face of new variants. Nature. 2021 Feb;590(7846):374–375. DOI:https://doi.org/10.1038/d41586-021-00367-7. PMID: 33580217.
- Liu Y, Liu J, Xia H, et al. Neutralizing activity of BNT162b2-elicited serum – preliminary report. N Engl J Med. 2021 Feb 17. DOI:https://doi.org/10.1056/NEJMc2102017. Epub ahead of print. PMID: 33596352
- Keller MD, Harris KM, Jensen-Wachspress MA, et al. SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. Blood. 2020 Dec 17;136(25):2905–2917. DOI:https://doi.org/10.1182/blood.2020008488. PMID: 33331927; PMCID: PMC7746091.
- Thomas S. The structure of the membrane protein of SARS-CoV-2 resembles the sugar transporter semiSWEET. Pathog Immun. 2020 Oct 19;5(1):342–363. DOI:https://doi.org/10.20411/pai.v5i1.377. PMID: 33154981; PMCID: PMC7608487.